All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

335

2012 to 2026

Breakthrough

335

Accelerated

74

Priority review

316

Orphan

234

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
201200
201321
2014104
20151010
20161110
20171911
20182018
2019169
20202011
2021219
20221313
202398
20241812
20252312
202687

335 approvals

Newest first. Hover a badge for what it means.

  • Lumvoa (Veligrotug-Vvze) · Viridian Therapeutics INCJun 26, 2026
    Original approval · BLA 761530NovelBreakthrough therapyPriority reviewApproval letter

    To treat thyroid eye disease

  • Ibrance (Palbociclib) · PfizerJun 24, 2026
    Efficacy supplement 24 · NDA 207103Breakthrough therapyApproval letter
  • Ibrance (Palbociclib) · PfizerJun 24, 2026
    Efficacy supplement 12 · NDA 212436Breakthrough therapyApproval letter
  • Tryngolza (Autoinjector) (Olezarsen Sodium) · Ionis Pharms INCJun 24, 2026
    Efficacy supplement 4 · NDA 218614Breakthrough therapyPriority reviewOrphanApproval letter
  • Hepcludex (Bulevirtide-Gmod) · Gilead Sciences INCMay 22, 2026
    Original approval · BLA 761468NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis

  • Enhertu (Fam-Trastuzumab Deruxtecan-Nxki) · Daiichi SankyoMay 15, 2026
    Efficacy supplement 43 · BLA 761139Breakthrough therapyPriority reviewOrphanApproval letter
  • Beqalzi (Sonrotoclax) · Beone Medicines USAMay 13, 2026
    Original approval · NDA 220711NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor

  • Bizengri (Zenocutuzumab-Zbco) · Merus N.V.May 8, 2026
    Efficacy supplement 10 · BLA 761352Breakthrough therapyPriority reviewOrphanApproval letter
  • Auvelity (Bupropion Hydrochloride, Dextromethorphan Hydrobromide) · AxsomeApr 30, 2026
    Efficacy supplement 18 · NDA 215430Breakthrough therapyPriority reviewApproval letter
  • Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc.Mar 24, 2026
    Original approval · BLA 761485NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)

  • Imcivree (Setmelanotide Acetate) · RhythmMar 19, 2026
    Efficacy supplement 9 · NDA 213793Breakthrough therapyPriority reviewOrphanApproval letter
  • Tecvayli (Teclistamab-Cqyv) · Janssen BiotechMar 5, 2026
    Efficacy supplement 18 · BLA 761291Breakthrough therapyPriority reviewOrphanApproval letter
  • Hernexeos (Zongertinib) · Boehringer IngelheimFeb 26, 2026
    Efficacy supplement 1 · NDA 219042Breakthrough therapyPriority reviewApproval letter
  • Loargys (Pegzilarginase-Nbln) · Immedica Pharma AbFeb 23, 2026
    Original approval · BLA 761211NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction

  • Zycubo (Copper Histidinate) · Sentynl Theraps INCJan 12, 2026
    Original approval · NDA 211241NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat Menkes disease

  • Yartemlea (Narsoplimab-Wuug) · Omeros CorpDec 23, 2025
    Original approval · BLA 761152NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

  • Jascayd (Nerandomilast) · Boehringer IngelheimDec 19, 2025
    Original approval · NDA 220449Breakthrough therapyPriority reviewOrphanApproval letter
  • Myqorzo (Aficamten) · CytokineticsDec 19, 2025
    Original approval · NDA 219083NovelBreakthrough therapyOrphanApproval letter

    To treat symptomatic obstructive hypertrophic cardiomyopathy

  • Enhertu (Fam-Trastuzumab Deruxtecan-Nxki) · Daiichi SankyoDec 15, 2025
    Efficacy supplement 38 · BLA 761139Breakthrough therapyPriority reviewOrphanApproval letter
  • Imfinzi (Durvalumab) · Astrazeneca Uk LTDNov 25, 2025
    Efficacy supplement 52 · BLA 761069Breakthrough therapyPriority reviewOrphanApproval letter
  • Voyxact (Sibeprenlimab-Szsi) · Otsuka Pharm CO LTDNov 25, 2025
    Original approval · BLA 761434NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression

  • Hyrnuo (Sevabertinib) · Bayer HealthcareNov 19, 2025
    Original approval · NDA 219972NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy

  • Redemplo (Plozasiran Sodium) · ArrowheadNov 18, 2025
    Original approval · NDA 219947NovelBreakthrough therapyOrphanApproval letter

    To reduce triglycerides in adults with familial chylomicronemia syndrome

  • Epkinly (Epcoritamab-Bysp) · Genmab US, Inc.Nov 18, 2025
    Efficacy supplement 9 · BLA 761324Breakthrough therapyPriority reviewOrphanApproval letter
  • Komzifti (Ziftomenib) · KuraNov 13, 2025
    Original approval · NDA 220305NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options

  • Kygevvi (Doxecitine, Doxribtimine) · Ucb INCNov 3, 2025
    Original approval · NDA 219792NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger

  • Gazyva (Obinutuzumab) · GenentechOct 17, 2025
    Efficacy supplement 37 · BLA 125486Breakthrough therapyApproval letter
  • Jascayd (Nerandomilast) · Boehringer IngelheimOct 7, 2025
    Original approval · NDA 218764NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat idiopathic pulmonary fibrosis

  • Evkeeza (Evinacumab-Dgnb) · Regeneron PharmaceuticalsSep 25, 2025
    Efficacy supplement 2 · BLA 761181Breakthrough therapyPriority reviewOrphanApproval letter
  • Inlexzo (Gemcitabine Hydrochloride) · Janssen BiotechSep 9, 2025
    Original approval · NDA 219683Breakthrough therapyPriority reviewApproval letter
  • Wegovy (Semaglutide) · NovoAug 15, 2025
    Efficacy supplement 24 · NDA 215256Breakthrough therapyPriority reviewApproval letter
  • Brinsupri (Brensocatib) · Insmed INCAug 12, 2025
    Original approval · NDA 217673NovelBreakthrough therapyPriority reviewApproval letter

    To treat non-cystic fibrosis bronchiectasis

  • Hernexeos (Zongertinib) · Boehringer IngelheimAug 8, 2025
    Original approval · NDA 219042NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy

  • Zegfrovy (Sunvozertinib) · DizalJul 2, 2025
    Original approval · NDA 219839NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based chemotherapy

  • Datroway (Datopotamab Deruxtecan-Dlnk) · Daiichi Sankyo INCJun 23, 2025
    Original approval · BLA 761464NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
  • Yeztugo (Lenacapavir Sodium) · Gilead Sciences INCJun 18, 2025
    Original approval · NDA 220020NovelBreakthrough therapyPriority reviewApproval letter
  • Yeztugo (Lenacapavir, Lenacapavir Sodium) · Gilead Sciences INCJun 18, 2025
    Original approval · NDA 220018NovelBreakthrough therapyPriority reviewApproval letter
  • Ibtrozi (Taletrectinib Adipate) · NuvationJun 11, 2025
    Original approval · NDA 219713NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer

  • Mavyret (Glecaprevir, Pibrentasvir) · AbbvieJun 10, 2025
    Efficacy supplement 5 · NDA 215110Breakthrough therapyPriority reviewOrphanApproval letter
  • Mavyret (Glecaprevir, Pibrentasvir) · AbbvieJun 10, 2025
    Efficacy supplement 19 · NDA 209394Breakthrough therapyPriority reviewOrphanApproval letter
  • Emrelis (Telisotuzumab Vedotin-Tllv) · Abbvie INCMay 14, 2025
    Original approval · BLA 761384NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy

  • Avmapki Fakzynja CO-Pack (Copackaged) (Avutometinib Potassium, Defactinib Hydrochloride) · Verastem INCMay 8, 2025
    Original approval · NDA 219616NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy

  • Penpulimab-Kcqx (Penpulimab-Kcqx) · Akeso BiopharmaApr 23, 2025
    Original approval · BLA 761258NovelBreakthrough therapyOrphanApproval letter

    In combination with either cisplatin or carboplatin and gemcitabine, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC), or as a single agent while on or after platinum-based chemotherapy and at least one other prior line of therapy

  • Uplizna (Inebilizumab-Cdon) · Viela BioApr 3, 2025
    Efficacy supplement 3 · BLA 761142Breakthrough therapyPriority reviewOrphanApproval letter
  • Vykat Xr (Diazoxide Choline) · SolenoMar 26, 2025
    Original approval · NDA 216665Breakthrough therapyPriority reviewOrphanApproval letter
  • Fabhalta (Iptacopan Hydrochloride) · NovartisMar 20, 2025
    Efficacy supplement 4 · NDA 218276Breakthrough therapyPriority reviewOrphanApproval letter
  • Journavx (Suzetrigine) · Vertex Pharms INCJan 30, 2025
    Original approval · NDA 219209NovelBreakthrough therapyPriority reviewApproval letter

    To treat moderate to severe acute pain

  • Enhertu (Fam-Trastuzumab Deruxtecan-Nxki) · Daiichi SankyoJan 27, 2025
    Efficacy supplement 32 · BLA 761139Breakthrough therapyPriority reviewOrphanApproval letter
  • Spravato (Esketamine Hydrochloride) · Janssen PharmsJan 17, 2025
    Efficacy supplement 16 · NDA 211243Breakthrough therapyPriority reviewApproval letter
  • Lumakras (Sotorasib) · Amgen INCJan 16, 2025
    Efficacy supplement 9 · NDA 214665Breakthrough therapyPriority reviewOrphanApproval letter
Page 1 of 7Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.